BioStem Technologies, Inc. (OTC: BSEM) reported Q2 EPS of ($0.52), $0.56 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $6.14 million versus the consensus estimate of $64.2 million.

2026 Financial Outlook

BioStem expects its revenue for full year 2026 to be in the range of $25 million to $29 million.

For earnings history and earnings-related data on BioStem Technologies, Inc. (BSEM) click here.